Abstracts Archive - Page 869 of 2425 - ACR Meeting Abstracts

Abstract Number: 1659 • 2019 ACR/ARP Annual Meeting
Linaclotide for the Treatment of Gastrointestinal Symptoms in Systemic Sclerosis
Eric Dein¹, John Clarke ², Frederick Wigley ³ and Zsuzsanna McMahan* ³, ¹Johns Hopkins, Baltimore, MD, ²Stanford, Pao Alto, ³Johns Hopkins University, Division of Rheumatology, Baltimore
Background/Purpose: Gastrointestinal (GI) involvement is the most common internal organ affected in systemic sclerosis (SSc). Constipation is a common GI complication in SSc that affects…
Abstract Number: 1660 • 2019 ACR/ARP Annual Meeting
Serial Sublingual Videomicroscopy in Systemic Sclerosis Clinic: Are the Microcirculation Measurements Correlated with Gastrointestinal Symptoms?
Tracy Frech¹, Guo Wei ² and Maureen Murtaugh ³, ¹Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Utah and Salt Lake VAMC, Salt Lake City
Background/Purpose: Intravital microscopy of the sublingual microcirculation provides estimates of perfused barrier region (PBR) and red blood cell fraction (RBCfract), which quantifies vasculopathy and, similar…
Abstract Number: 1661 • 2019 ACR/ARP Annual Meeting
Circulating Cell Free DNA Released from Eosinophils Is a Practical Biomarker in Patients with Eosinophilic Granulomatosis with Polyangiitis
Teppei Hashimoto¹, Yuichi Yokoyama ², Tetsuya Furukawa ³, Takahiro Yoshikawa ³, Naoto Azuma ², Kohsuke Yoshida ⁴, Akira Hashiramoto ⁴ and Kiyoshi Matsui ³, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Kobe, Hyogo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ³Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan, ⁴Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan
Background/Purpose: Fragmented cell-free DNA (cfDNA) is released into blood circulation as results of damage or death of peripheral blood cells as well as organ tissues,…
Abstract Number: 1662 • 2019 ACR/ARP Annual Meeting
Does PR3-ANCA+ Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)Really Exist?
Matthias Papo¹, Renato A. Sinico ², Vítor Teixeira ³, Maria-Letizia Urban ⁴, Juliane Mahrhold ⁵, Francesco Locatelli ⁶, Giulia Cassone ⁷, Franco Schiavon ⁸, Benjamin Seeliger ⁹, Thomas Neumann ¹⁰, Claus Kroegel ¹¹, Matthieu Groh ¹², Chiara Marvisi ¹³, Maxime Samson ¹⁴, Thomas Barba ¹⁵, David Jayne ¹⁶, Bernhard Hellmich ⁵, Sara Monti ¹⁷, Carlomaurizio Montecucco ⁶, Carlo Salvarani ¹⁸, Jean-Emmanuel Kahn ¹², Cécile-Audrey Durel ¹⁵, Loic Guillevin ¹⁹, Giacomo Emmi ⁴, Augusto Vaglio ²⁰ and Benjamin Terrier ¹⁹, ¹Department of Internal Medicine, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Paris, France, Paris, France, ²Department of Medicine and Surgery, Università degli Studi di Milano - Bicocca , Italy, Milan, Italy, ³Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Lisbon, Portugal., Lisbon, Portugal, ⁴Department of Experimental and Clinical Medicine, University of Firenze, Florence, Italy, Florence, Italy, ⁵Department of Internal Medicine, Rheumatology and Immunology, Vasculitis-Center Tübingen-Kirchheim, Medius Klinik Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, Kirchheim, Germany, ⁶Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, ⁷Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy. Rheumatology Unit, IRCCS Arcispedale Santa Maria Nuova, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, Modena and Reggio Emilia, Italy, ⁸Operative Unit of Rheumatology, Department of Medicine DIMED, University of Padova, Padova, Italy, Padova, Italy, ⁹Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, Hannover, Germany, ¹⁰Division of Rheumatology and Immunolog, Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland, ¹¹Department of Pneumology and Allergology, Clinic of Internal Medicine I, Jena University Hospital, Jena, Germany, Jena, Germany, ¹²Service de Médecine Interne, Centre de Référence des Syndromes Hyperéosinophiliques-CEREO, Hôpital Foch, Université Versailles–Saint-Quentin-en-Yvelines, Suresnes, France, Suresnes, France, ¹³Nephrology Unit, Parma University Hospital, Parma, Italy, Parma, Italy, ¹⁴CHU Dijon, Dijon, France, ¹⁵Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ¹⁶Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ¹⁷University of Pavia, Pavia, Italy, ¹⁸Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹⁹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ²⁰Nephrology Unit, Parma University Hospital, Parma, Italy, Nephrology Unit, Parma University Hospital, Parma, Italy, Italy
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) (Churg–Strauss) is a small-vessel necrotizing vasculitis characterized by blood and tissue eosinophilia and asthma. Only a third of EGPA…
Abstract Number: 1663 • 2019 ACR/ARP Annual Meeting
Assessments of Quality of Life in Patients with Eosinophilic Granulomatosis with Polyangiitis
Gunnar Tomasson¹, Christian Pagnoux ², David Cuthbertson ³, Simon Carette ², Nader A. Khalidi ⁴, Curry L. Koening ⁵, Carol Langford ⁶, Carol A. McAlear ⁷, Larry Moreland ⁸, Paul Monach ⁹, Philip Seo ¹⁰, Antoine Sreih ¹¹, Steven Ytterberg ¹² and Peter Merkel ¹¹, ¹Faculty of Medicine, University of Iceland and Landpitali University Hospital, Reykjavik, Iceland, ²Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ³University of South Florida, Tampa, FL, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Utah Hospital, Salt Lake City, UT, ⁶Cleveland Clinic, Cleveland, OH, ⁷University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, ⁸University of Pittsburgh, PITTSBURGH, PA, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰Johns Hopkins Medicine, Baltimore, MD, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by asthma and other manifestations of vasculitis, some of which can be life-threatening, cause major organ damage,…
Abstract Number: 1664 • 2019 ACR/ARP Annual Meeting
Reducing the Number of Rituximab Infusions at Onset of Maintenance Therapy for ANCA-associated Vasculitides: Results of a Post Hoc Analysis from a Randomized–controlled Trial
Pierre Charles¹, Agnes Dechartres ², Benjamin Terrier ³, Pascal Cohen ³, Stanislas Faguer ⁴, Antoine Huart ⁴, Mohamed Hamidou ⁵, Christian Agard ⁵, Bernard Bonnotte ⁶, Maxime Samson ⁷, Alexandre Karras ⁸, Noémie Jourde-Chiche ⁹, François Lifermann ¹⁰, Pierre Gobert ¹¹, Catherine Hanrotel-Saliou ¹², Pascal Godmer ¹³, Nicolas Martin-Silva ¹⁴, Grégory Pugnet ¹⁵, Marie Matignon ¹⁶, Olivier Aumaitre ¹⁷, Jean-François Viallard ¹⁸, François Maurier ¹⁹, Nadine Meaux Ruault ²⁰, Sophie Rivière ²¹, Jean Sibilia ²², Xavier Puéchal for the French Vasculitis Study Group ³, Luc Mouthon ³ and Loic Guillevin ³, ¹Institut Mutualiste Montsouris, Paris, France, ²APHP, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ⁴CHU Toulouse, Toulouse, France, ⁵CHU Nantes, Nantes, France, ⁶Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon ; Université Bourgogne-Franche Comté, INSERM, EFS BFC, UMR1098, F-21000 Dijon, Dijon, France, ⁷CHU Dijon, Dijon, France, ⁸Paris HEGP, Paris, France, ⁹APHM, Marseille, Marseille, France, ¹⁰CH Dax, Dax, France, ¹¹CH Avignon, Avignon, France, ¹²CHU Brest, Brest, France, ¹³CH Bretagne-Atlantique, Vannes, France, ¹⁴CHU Caen, Caen, France, ¹⁵CHU de Toulouse, Hôpital Purpan, Service de Médecine Interne, Toulouse, France, ¹⁶APHP, Créteil, France, ¹⁷CHU Clermont Ferrand, Clermont Ferrand, France, ¹⁸CHU Bordeaux, Bordeaux, France, ¹⁹Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ²⁰CHU Besançon, Besançon, France, ²¹CHU Montpellier, Montpellier, France, ²²CHU Strasbourg, Strasbourg, France
Background/Purpose: Rituximab (RTX) superiority over azathioprine to maintain ANCA-associated vasculitis (AAV) remission was demonstrated.The MAINRITSAN2 trial was designed to compare an individually tailored RTX-infusion schedule…
Abstract Number: 1665 • 2019 ACR/ARP Annual Meeting
Glucocorticoids in Incident ANCA-Associated Vasculitis (AAV) Patients – A Study of Routine Clinical Practice in the EU Demonstrates Prolonged Use and Temporal Relationship to Adverse Events and Infections
Dieter Goette¹ and Peter Rutherford ¹, ¹Vifor Pharma, Zurich, Zurich, Switzerland
Background/Purpose: AAV is a severe systemic vasculitis and rapid induction of remission is essential and high dose glucocorticoids (GC) are part of standard of care.…
Abstract Number: 1666 • 2019 ACR/ARP Annual Meeting
Maintenance Treatment in ANCA Associated Vasculitis in Real World Clinical Practice – Burden of Disease, Use of Glucocorticoids and Impact on Patient Functional Status Remain Major Problems
Dieter Goette¹ and Peter Rutherford ¹, ¹Vifor Pharma, Zurich, Zurich, Switzerland
Background/Purpose: After successful remission induction AAV is a relapsing remitting long term condition and patients are at risk of organ damage from both active AAV…
Abstract Number: 1667 • 2019 ACR/ARP Annual Meeting
Long Term Outcome of Hydralazine-Associated Vasculitis
Saja Almaaitah¹, Kinanah Yaseen ², Yuxuan Jin ³ and Rula Hajj-ali ⁴, ¹Internal Medicine Residency/Cleveland Clinic, University Heights, OH, ²Cleveland Clinic, Cleveland, OH, ³Quantitative Health Science, Cleveland Clinic, Cleveland, OH, ⁴Rheumatologic and Immunologic Disease/Cleveland Clinic, Cleveland, OH
Background/Purpose: Hydralazine associated vasculitis (HAV) is rare but with potentially detrimental complications, affecting different organ systems. Most case series described short term disease course. Hence,…
Abstract Number: 1668 • 2019 ACR/ARP Annual Meeting
Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Registry
Michele Iudici¹, Christian Pagnoux ², Delphine Courvoisier ³, Pascal Cohen ⁴, Mohamed Hamidou ⁵, Achille Aouba ⁶, François Lifermann ⁷, Marc Ruivard ⁸, Olivier Aumaitre ⁹, Bernard Bonnotte ¹⁰, François Maurier ¹¹, Olivier Decaux ¹², Eric Hachulla ¹³, Alexandre Karras ¹⁴, Chahéra Khouatra ¹⁵, Noémie Jourde-Chiche ¹⁶, Jean-François Viallard ¹⁷, Claire Blanchard-Delaunay ¹⁸, Pascal Godmer ¹⁹, Alain Le Quellec ²⁰, Thomas Quémeneur ²¹, Claire de Moreuil ²², Alexis Régent ⁴, Benjamin Terrier ⁴, Luc Mouthon ⁴, Loic Guillevin ⁴ and Xavier Puéchal for the French Vasculitis Study Group ⁴, ¹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, France and Division of Rheumatology, Department of Internal Medicine Specialties, Geneva University Hospitals, Switzerland, Geneva, Geneve, Switzerland, ²National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin and Toronto Canada, Paris, France, ³Division of Rheumatology, Geneva University Hospital, Switzerland, Geneva, Switzerland, ⁴National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ⁵CHU Nantes, Nantes, France, ⁶CHU Caen, Caen, France, ⁷CH Dax, Dax, France, ⁸CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁹CHU Clermont Ferrand, Clermont Ferrand, France, ¹⁰Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon ; Université Bourgogne-Franche Comté, INSERM, EFS BFC, UMR1098, F-21000 Dijon, Dijon, France, ¹¹Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ¹²CHU Rennes, Rennes, France, ¹³CHU Lille, Lille, France, ¹⁴Paris HEGP, Paris, France, ¹⁵CHU Lyon, Lyon, France, ¹⁶APHM, Marseille, Marseille, France, ¹⁷CHU Bordeaux, Bordeaux, France, ¹⁸CH Niort, Niort, France, ¹⁹CH Bretagne-Atlantique, Vannes, France, ²⁰CHU Montpellier, Montpellier, France, ²¹CH Valenciennes, Valenciennes, France, ²²CHU Brest, Brest, France
Background/Purpose: The long-term features of granulomatosis with polyangiitis (GPA), a systemic small-vessel ANCA-associated necrotizing vasculitis, have been mainly reported in small patient series. The aim…
Abstract Number: 1669 • 2019 ACR/ARP Annual Meeting
Comparison of Mizoribine with Azathioprine in Efficacy and Safety for ANCA-Associated Vasculitis
Sho Fukui ¹, Satoshi Kawaai¹, Genki Kidoguchi ¹, Takehiro Nakai ², Hiroki Ozawa ¹, Ayako Koido ¹, Yukihiko Ikeda ¹, Masei Suda ¹, Haruyuki Yanaoka ¹, Hisanori Shimizu ¹, Hiromichi Tamaki ¹, Tokutaro Tsuda ¹, Mitsumasa Kishimoto ³, Kenichi Yamaguchi ¹ and Masato Okada ¹, ¹St.Luke International Hospital Immuno-Rheumatology Center, Tokyo, Japan, ²St.Luke International Hospital Immuno-Rheumatology Center, Tokyo, Tokyo, Japan, ³Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan
Background/Purpose: Mizoribine (MZR) is an immunosuppressant working as an inhibitor of purine synthesis, which mechanism of action is similar to mycophenolate mofetil. MZR is approved…
Abstract Number: 1670 • 2019 ACR/ARP Annual Meeting
Evaluation of Subclinical Coronary Atherosclerosis in ANCA-associated Small Vessel Vasculitides (AAVs) Compared to Matched Controls Through Visual Assessment of Coronary Arterial Calcium (CAC) Score Using Non-Gated Chest Computed Tomography (CT)
Sohail Farshad¹, Alexandra Halalau ², Sayf Al-Katib ³, Julie George ⁴ and Elena Schiopu ⁵, ¹Department of Internal Medicine, Beaumont Health System, Royal Oak, MI, ²Department of Internal Medicine, Beaumont Health System, Royal Oak, ³Department of Radiology, Beaumont Health System, Royal Oak, MI, ⁴Beaumont Health System, Royal Oak, MI, ⁵Department of Rheumatology, University of Michigan, Ann Arbor
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is the most prevalent adult vasculitis and is associated with significant inflammatory burden; chest computed tomography (CT)…
Abstract Number: 1671 • 2019 ACR/ARP Annual Meeting
Hospital Admissions and Mortality in Patients with ANCA-associated Vasculitis
Jon Golenbiewski¹, Amanda Eudy ², Megan Clowse ² and Nancy Allen ², ¹Duke University, Durham, NC, ²Duke University, Durham
Background/Purpose: ANCA-associated vasculitis (AAV) has a high rate of complications, both from disease itself and treatments. Hospital mortality rates for AAV range between 10-20%. There…
Abstract Number: 1672 • 2019 ACR/ARP Annual Meeting
Use of Rituximab for the Treatment of ANCA-Associated Vasculitis in Canada, 2010-2018
Arielle Mendel¹, Simon Carette ² and Christian Pagnoux ², ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Mount Sinai Hospital and University Health Network, Toronto, ON, Canada
Background/Purpose: Rituximab (RTX) is an effective therapy for ANCA-Associated Vasculitis (AAV). The Canadian Vasculitis Research Network (CanVasc) recommends RTX for induction among patients with unacceptable risk…
Abstract Number: 1673 • 2019 ACR/ARP Annual Meeting
Factors Associated with Overall and First-Year Mortality in Turkish Patients with ANCA-Associated Vasculitides: Retrospective, Multicentre Trial
Onay Gercik¹, Emre Bilgin ², Dilek Solmaz ¹, Irfan Ocal ³, Arzu Saglam ⁴, Riza Kardas ⁵, Ozge Aybi ⁵, Gokhan Kabadayi ⁶, Zeki Soypacaci ⁷, İdil Kurut Aysin ⁸, Tolga Yildirim ⁹, Omer Karadag ¹⁰ and Servet Akar ¹¹, ¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, ³Izmir Katip Celebi University, Faculty of Medicine, Department of Pathology, Izmir, Turkey, ⁴Hacettepe University, Faculty of Medicine, Department of Pathology, Ankara, Turkey, ⁵Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ⁶Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ⁷Izmir Katip Celebi University Faculty of Medicine, Department of Internal Medicine, Division of Nephrology, Izmir, Turkey, ⁸Izmir Katip Celebi University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ⁹Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Nephrology, Ankara, Turkey, ¹⁰Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, ankara, Turkey, ¹¹Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey
Background/Purpose: Overall mortality in ANCA-associated vasculitides (AAVs) over the last two decades has been reported to be decreasing with the use of immunosuppressive therapies. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].